Nanoparticle-mediated therapeutic compounds delivery to glioblastoma

Besides significant advances, a more successful design of nanocarriers for efficient BBB crossing and delivery of diagnostic and/or therapeutic molecules to CNS will be needed to achieve efficient nanomedicine-based therapeutics for glioblastoma. This will require a significant effort in improving the chemical architecture of nanocarriers, identifying the critical design parameters that might play a key role in facilitating both BBB crossing and GBM selective targeting.